Australia’s Pharmaceutical Benefits Scheme (PBS) cost-control initiative for medicines has become a focal point of economic and trade debates between Australia and the United States. Countries around the world admire and envy the Australian PBS scheme. This week the Australian government pledged to make medicines even cheaper. This has prompted a backlash from US Pharmaceutical companies who are worried about their profits in Australia and the possibilities other countries could follow suit. Could Cheap Medicines in Australia be the catalyst that spark greater animosity between Australia and the US?
How the PBS Keeps Medicines Cheap in Australia
The Pharmaceutical Benefits Scheme (PBS) is an essential part of Australia’s healthcare system, designed to make medicines affordable for everyone. Last year, Australians received 227 million prescriptions under the scheme.
Here’s how it works: the PBS includes a list of medications that the Australian government subsidises. If a medicine you need is on this list, the government covers most of the cost. For example, even if a medication costs thousands of dollars, people with a prescription only pay a small, fixed amount per script.
At the moment, concession cardholders pay just $7.70 per prescription, while everyone else with a Medicare card pays no more than $31.60. However, starting next year, this maximum cost for non-concession holders will drop to $25. This change is due to a promise from the Albanese government, which, notably, has also been supported by the Coalition.
The PBS also includes a safety net for those who need a lot of medications. Once concession cardholders spend $277.20 in a year, or general patients reach $1,694, they won’t pay any more for medicines listed under the PBS for the rest of the year.
Through this system, the PBS ensures that life-saving medications remain accessible, without pushing people into financial hardship.
US Pharmaceutical Giants Challenge Australia’s PBS Policies
US pharmaceutical companies have long expressed grievances about Australia’s Pharmaceutical Benefits Scheme (PBS), primarily because of its impact on their profits. Specifically, the PBS controls drug prices to make essential medicines more affordable; however, this move significantly impacts the earnings of big pharmaceutical firms.
These companies also argue that the PBS approval process is too slow. They claim this delays their products from reaching Australian pharmacies, effectively denying them full market access.
The peak industry body for these companies, the Pharmaceutical Research and Manufacturers of America (known as PhRMA), recently raised a formal complaint with the Trump administration. Among its members are pharmaceutical giants like Johnson & Johnson, Pfizer, Merck & Co, Eli Lilly, Bristol Myers Squibb, Novo Nordisk, CSL, and Amgen.
PhRMA accuses Australia, along with other nations, of having unfair pricing policies that result in substantial profit losses. They estimate these “discriminatory” and “egregious” policies threaten billions in lost sales, weaken American competitiveness, and harm jobs and exports.
The Australian PBS scheme faces mounting pressure as US pharmaceutical companies will continue lobbying the US government to oppose its practices. This ongoing tension highlights the challenge Australia faces in maintaining a balance between making medicines affordable for its citizens and avoiding the wrath of powerful international pharmaceutical industries. Will cheap medicines in Australia continue to be a reality?
Source
Explore more entrepreneurial insights and success stories at Inspirepreneur, your go-to magazine for business innovation and leadership.
